Table 1 Patient characteristics
From: A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer
Baseline characteristics | n =12 |
|---|---|
Median age, years (range) | 64 (49–70) |
ECOG performance status | |
PS=0 | 4 |
PS=1 | 8 |
Type | |
ER positive and PgR positive | 8 |
HER-2 positive | 0 |
ER negative/PgR negative/HER-2 negative | 4 |
Site of metastases | |
Liver | 6 |
Lung | 8 |
Bone | 9 |
Lymph node | 3 |
No. of prior chemotherapy regimens | |
2 Regimens | 2 |
4 Regimens | 6 |
5 Regimens | 3 |
7 Regimens | 1 |
Prior chemotherapy agents | |
Anthracycline | 12 (100%) |
Taxane | 12 (100%) |
Capecitabine | 6 (50%) |
Vinorelbine | 2 (13%) |
